Furthermore, NSCLC with concurrent STK11 and KEAP1 mutations exhibit distinct Gln metabolism patterns compared to NSCLC with KEAP1 mutation alone, suggesting that the antitumor effects of targeting Gln metabolism may vary among NSCLC subgroups with different mutation co-occurring patterns (99). Here, STK11 is linked to non-small cell lung carcinoma.